AR122286A1 - Anticuerpos potenciadores del factor h y usos de estos - Google Patents

Anticuerpos potenciadores del factor h y usos de estos

Info

Publication number
AR122286A1
AR122286A1 ARP200102011A ARP200102011A AR122286A1 AR 122286 A1 AR122286 A1 AR 122286A1 AR P200102011 A ARP200102011 A AR P200102011A AR P200102011 A ARP200102011 A AR P200102011A AR 122286 A1 AR122286 A1 AR 122286A1
Authority
AR
Argentina
Prior art keywords
sequence
seq
nucleic acid
antibody
heavy chain
Prior art date
Application number
ARP200102011A
Other languages
English (en)
Inventor
Scott Lauder
Tom Purcell
Sridhar Govindarajan
Original Assignee
Gemini Therapeutics Sub Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemini Therapeutics Sub Inc filed Critical Gemini Therapeutics Sub Inc
Publication of AR122286A1 publication Critical patent/AR122286A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Reivindicación 1: Un anticuerpo aislado, sintético o recombinante o un fragmento de unión al antígeno de este que se une específicamente al dominio de la proteína de control del complemento 18 (CCP18) del factor H (FH) que comprende lo siguiente: una secuencia de CDR1 de cadena ligera que comprende la secuencia SSVTY (SEQ ID nº 1) o la secuencia TSVTY (SEQ ID nº 13), una secuencia de CDR2 de cadena ligera que comprende la secuencia ATS (SEQ ID nº 2) o la secuencia ASS (SEQ ID nº 14), una secuencia de CDR3 de cadena ligera que comprende la secuencia QHRSSSNPLT (SEQ ID nº 3), una secuencia de CDR1 de cadena pesada que comprende la secuencia GFSLTNYG (SEQ ID nº 5), una secuencia de CDR2 de cadena pesada que comprende la secuencia VWSGGTT (SEQ ID nº 6) o la secuencia de IWSGGTT (SEQ ID nº 10) y una secuencia de CDR3 de cadena pesada que comprende la secuencia ARNFGNYAMDY (SEQ ID nº 7) o la secuencia ARNFGNYAMDF (SEQ ID nº 11). Reivindicación 21: Un ácido nucleico aislado, sintético o recombinante que comprende una secuencia de ácido nucleico que codifica el anticuerpo o fragmento según cualquiera de las reivindicaciones 1 a 20. Reivindicación 22: Un vector que comprende un ácido nucleico según la reivindicación 21. Reivindicación 25: Una célula recombinante que comprende el ácido nucleico según la reivindicación 21 o el vector según cualquiera de las reivindicaciones 22 - 24. Reivindicación 26: Una composición farmacéutica que comprende el anticuerpo o fragmento según cualquiera de las reivindicaciones 1 a 20, el ácido nucleico según la reivindicación 21, el vector según cualquiera de las reivindicaciones 22 - 24 o la célula recombinante según la reivindicación 25 y un portador, diluyente y/o excipiente farmacéuticamente aceptable.
ARP200102011A 2019-07-17 2020-07-17 Anticuerpos potenciadores del factor h y usos de estos AR122286A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962875309P 2019-07-17 2019-07-17

Publications (1)

Publication Number Publication Date
AR122286A1 true AR122286A1 (es) 2022-08-31

Family

ID=74211270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102011A AR122286A1 (es) 2019-07-17 2020-07-17 Anticuerpos potenciadores del factor h y usos de estos

Country Status (13)

Country Link
US (1) US11820814B2 (es)
EP (1) EP3999073A4 (es)
JP (1) JP2022541275A (es)
KR (1) KR20220057530A (es)
CN (1) CN114828886A (es)
AR (1) AR122286A1 (es)
AU (1) AU2020313981A1 (es)
BR (1) BR112022000739A2 (es)
CA (1) CA3147638A1 (es)
IL (1) IL289812A (es)
MX (1) MX2022000725A (es)
TW (1) TW202110893A (es)
WO (1) WO2021011903A1 (es)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
WO2006012621A2 (en) 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
CN101809034B (zh) 2007-06-07 2015-07-08 健泰科生物技术公司 C3b抗体及用于预防和治疗补体相关病症的方法
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
WO2011047146A2 (en) 2009-10-14 2011-04-21 Centocor Ortho Biotech Inc. Methods of affinity maturing antibodies
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
AU2011301996A1 (en) 2010-09-15 2013-03-21 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
GB201318170D0 (en) * 2013-10-14 2013-11-27 Univ Edinburgh Proteins with Diagnostic and Therapeutic Uses
US20160297892A1 (en) 2013-11-07 2016-10-13 Novo Nordisk A/S Novel Methods and Antibodies for Treating Coagulapathy
WO2015070207A2 (en) 2013-11-11 2015-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
US10112993B2 (en) * 2014-08-20 2018-10-30 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
CA2959356C (en) 2014-08-27 2024-02-20 Memorial Sloan Kettering Cancer Center Novel antibodies that bind to b7h3
WO2017114401A1 (zh) * 2015-12-31 2017-07-06 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用
KR20190003951A (ko) * 2016-04-04 2019-01-10 바이오버라티브 유에스에이 인코포레이티드 항-보체 인자 bb 항체 및 이의 용도
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
KR102566634B1 (ko) * 2016-06-28 2023-08-14 우니베르시테트 울름 보체 억제제 및 그의 용도
US10865238B1 (en) * 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
KR20200110688A (ko) * 2018-01-15 2020-09-24 스티흐팅 산퀸 불드포르지닝 인자 h 강화 항체 및 이의 사용

Also Published As

Publication number Publication date
IL289812A (en) 2022-03-01
CA3147638A1 (en) 2021-01-21
BR112022000739A2 (pt) 2022-04-12
US20220372120A1 (en) 2022-11-24
AU2020313981A1 (en) 2022-03-03
KR20220057530A (ko) 2022-05-09
JP2022541275A (ja) 2022-09-22
CN114828886A (zh) 2022-07-29
EP3999073A4 (en) 2023-07-26
MX2022000725A (es) 2022-04-26
US11820814B2 (en) 2023-11-21
EP3999073A1 (en) 2022-05-25
WO2021011903A1 (en) 2021-01-21
TW202110893A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
AR106991A1 (es) Anticuerpos neutralizantes del virus de inmunodeficiencia humana
AR109715A1 (es) Anticuerpos anti-cd27
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
ECSP18084153A (es) Anticuerpos anti-BASIGIN humanizados y uso de los mismos
AR110755A1 (es) Anticuerpos dirigidos a hueso
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
AR103839A1 (es) DÍMEROS scFv-Fc QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS
AR124084A1 (es) ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO
RU2021128024A (ru) Способы культивирования клеток
AR122286A1 (es) Anticuerpos potenciadores del factor h y usos de estos
AR123671A1 (es) Anticuerpo fn14 anti-humano
AR125040A1 (es) Constructos anti-vista y usos de estos
AR125212A1 (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
PE20240363A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
PE20220763A1 (es) Materiales y metodos para modular la inmunidad mediada por celulas t
AR116937A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20